Clinical Trials Logo

Bacterial Overgrowth Syndrome clinical trials

View clinical trials related to Bacterial Overgrowth Syndrome.

Filter by:
  • None
  • Page 1

NCT ID: NCT04755673 Completed - Clinical trials for Irritable Bowel Syndrome

Atrantil for Intestinal Bacterial Overgrowth

Start date: September 18, 2020
Phase: N/A
Study type: Interventional

Intestinal Bacterial Overgrowth (IBO) is a common functional condition due to excessive amounts of bacteria in the gastrointestinal tract. These bacteria ferment ingested food resulting in the production of hydrogen, methane, and carbon dioxide which subsequently can induce GI symptoms including abdominal pain, bloating, distention, diarrhea and constipation. Typically this condition is treated with antibiotics but for a portion of patients symptoms often recur. Recent work suggests that increased methane production may emanate from overgrowth of a specific type of archaebacteria, causing the aforementioned symptoms. However, no current therapies exist to treat this phenomenon. The investigators propose to trial the supplement Atrantil on patients with IMO in order to study the supplements impact on symptoms, quality of life, and methane levels.

NCT ID: NCT02819037 Completed - Gastric Bypass Clinical Trials

Small Intestinal Bacterial Overgrowth Obese

SIBOB
Start date: May 27, 2016
Phase: N/A
Study type: Interventional

The objective of this research is to determine the incidence of microbial overgrowth of the small intestine before and after a gastric bypass. For this purpose, the study is based on the analysis of the expired hydrogen H2 with gas chromatography before surgery and at 1, 3, 6, 12, 18 and 24 months.